SCHEDULE: Vanguard Group Reports Zero Arcturus Therapeutics Stake

The Vanguard Group has reported zero beneficial ownership in Arcturus Therapeutics Holdings Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 3 to Schedule 13G for Arcturus Therapeutics Holdings Inc. (CUSIP: 03969T109).
• The filing indicates that The Vanguard Group now beneficially owns 0 shares of Arcturus Therapeutics common stock, representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• As a result of the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately, and The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over these securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event from Vanguard's perspective, reflecting an internal organizational change rather than a direct positive or negative assessment of Arcturus Therapeutics. For Arcturus, the market perception could be slightly negative due to the reported zero ownership, but the underlying reason is procedural.

Positives

• The Vanguard Group is demonstrating compliance with SEC reporting requirements by updating its beneficial ownership status in accordance with SEC Release No. 34-39538.

Negatives

• The reporting of zero beneficial ownership by a major institutional investor like The Vanguard Group could be perceived negatively by the market for Arcturus Therapeutics, despite the stated reason being an internal realignment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Arcturus Therapeutics' future performance or The Vanguard Group's future investment intentions.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard regulatory disclosures for institutional investors to report changes in their beneficial ownership. This specific filing reflects an internal organizational change at Vanguard, which is a common practice for large asset managers to optimize reporting structures, rather than a strategic divestment based on Arcturus Therapeutics' operational performance.

Stakeholder Impact

• Shareholders of Arcturus Therapeutics might interpret the reporting of zero beneficial ownership by a significant institutional investor as a negative signal, potentially leading to short-term market reaction, even though the stated reason is an internal restructuring at Vanguard.

Key Dates

Recommendation

This filing primarily reflects an internal organizational change at The Vanguard Group, leading to a disaggregated reporting of beneficial ownership. It does not provide new information regarding Arcturus Therapeutics' operational performance or strategic direction, thus a 'hold' recommendation is appropriate as no new fundamental drivers are presented.

Keywords

Arcturus Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Biotechnology